Literature DB >> 9780142

Negative regulation of human T cell activation by the receptor-type protein tyrosine phosphatase CD148.

S G Tangye1, J Wu, G Aversa, J E de Vries, L L Lanier, J H Phillips.   

Abstract

T cell activation represents a balance between positive and negative signals delivered via distinct cell surface molecules. Many cytoplasmic protein tyrosine phosphatases are involved in regulating cellular responses by antagonizing the action of protein tyrosine kinases. CD148 is a receptor-type protein tyrosine phosphatase expressed by all human mononuclear cells. We have investigated the effect of CD148 on TCR-mediated activation of human T cells. Overexpression of wild-type, but not a phosphatase-deficient, CD148 in Jurkat T cells inhibited TCR-mediated activation, evidenced by reduced expression of the early activation Ag CD69, inhibition of tyrosine phosphorylation of many intracellular proteins including the critical protein tyrosine kinase ZAP-70, and impairment of mitogen-activated protein kinase activation. Taken together, these results suggest that CD148 is an important phosphatase involved in negatively regulating the proximal signaling events during activation of Ag-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780142

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

Authors:  Keiko Takahashi; Raymond L Mernaugh; David B Friedman; Rebecca Weller; Nobuo Tsuboi; Hironobu Yamashita; Vito Quaranta; Takamune Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.

Authors:  Keiko Takahashi; Rachel H Kim; Lejla Pasic; Lilly He; Shinya Nagasaka; Daisuke Katagiri; Tracy May; Akira Shimizu; Raymond C Harris; Raymond L Mernaugh; Takamune Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

Review 3.  Evaluating function of transmembrane protein tyrosine phosphatase CD148 in lymphocyte biology.

Authors:  Thomas R Harrod; Louis B Justement
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation.

Authors:  J E Baker; R Majeti; S G Tangye; A Weiss
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

5.  A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.

Authors:  Takamune Takahashi; Keiko Takahashi; Raymond L Mernaugh; Nobuo Tsuboi; Hua Liu; Thomas O Daniel
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

6.  Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.

Authors:  Jin-Sung Chung; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2011-05-09       Impact factor: 5.532

7.  Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148.

Authors:  Ondrej Stepanek; Tomas Kalina; Peter Draber; Tereza Skopcova; Karel Svojgr; Pavla Angelisova; Vaclav Horejsi; Arthur Weiss; Tomas Brdicka
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

Review 8.  Protein tyrosine phosphatases in lymphocyte activation and autoimmunity.

Authors:  Inmoo Rhee; André Veillette
Journal:  Nat Immunol       Date:  2012-04-18       Impact factor: 25.606

Review 9.  Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells.

Authors:  Yacine Bounab; Andrew Getahun; John C Cambier; Marc Daëron
Journal:  Curr Opin Immunol       Date:  2013-05-15       Impact factor: 7.486

10.  The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor.

Authors:  Shaun-Paul Cordoba; Kaushik Choudhuri; Hao Zhang; Marcus Bridge; Alp Bugra Basat; Michael L Dustin; P Anton van der Merwe
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.